Medlab Clinical Limited
(ASX:MDC) has announced it has signed an agreement to start a study which compares how ‘NanoStat’ compares to taking statin tablets to lower cholesterol.
The medical research and development company says the global statin market is estimated to reach US$12 billion in 2018.
Medlab’s research shows that a more direct oral spray will enable smaller doses of statin tablets and that will reduce the statin side effects. Currently, a-third of patients experience pain side effects.
Medlab says positive outcomes of its study would lead to a wider take up of its NanoCelle Atorvastatin oral spray, ‘Nanostat’.
Medlab Clinical Limited
(ASX:MDC) reported a net loss of $1.7 million after tax for the six months to 31 December 2016.
